Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2019-06-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors, executives, and employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by the exchange.
2019-06-11 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회 결과' (Extraordinary General Meeting Results) and details the outcomes of shareholder voting on specific agenda items, such as the appointment of directors and the granting of stock options. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-06-11 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for Ensol Biosciences. It contains the meeting agenda, details on director appointments, and management reference materials (경영참고사항) including business overviews and product pipelines. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their participation/votes. In the context of the provided categories, this aligns with 'Proxy Solicitation & Information Statement'.
2019-05-27 Korean
기업설명회(IR)개최결과
Investor Presentation Classification · 95% confidence The document is a short, structured notification regarding the results of an Investor Relations (IR) meeting held by Ensol Biosciences. It lists the date, location, attendees, and agenda of the meeting, and explicitly mentions that the IR materials were distributed at the event and filed via the Korea Exchange's disclosure system. Since it is a brief announcement of an event and the availability of materials rather than the presentation deck itself, it falls under the category of a regulatory filing announcement.
2019-05-22 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling of an Investor Relations (IR) meeting. It provides details such as the date, time, location, and purpose of the meeting, and explicitly states that materials will be distributed at the event. Since it is an announcement of an upcoming event rather than the presentation materials themselves, it falls under the category of a regulatory filing announcement.
2019-05-14 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the results of a securities issuance (specifically convertible preferred shares via third-party allocation). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2019-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.